ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study

被引：0
|
作者：
Pahwa, R.
Tanner, C. M.
Hauser, R. A.
Nausieda, P.
Truong, D. D.
Hull, K.
Agarwal, P.
Johnson, R.
Ruby, A. E.
McClure, N. L.
Stempien, M. J.
机构：
来源：
MOVEMENT DISORDERS | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2012
引用
收藏
页码：S663 / S663
页数：1
相关论文
共 45 条
  • [1] ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) A Randomized Clinical Trial
    Pahwa, Rajesh
    Tanner, Caroline M.
    Hauser, Robert A.
    Isaacson, Stuart H.
    Nausieda, Paul A.
    Truong, Daniel D.
    Agarwal, Pinky
    Hull, Keith L.
    Lyons, Kelly E.
    Johnson, Reed
    Stempien, Mary Jean
    JAMA NEUROLOGY, 2017, 74 (08) : 941 - 949
  • [2] Efficacy and safety of ADS-5102 (amantadine) extended-release capsules for treating levodopa-induced dyskinesia
    Agarwal, Pinky
    Ray, Sudeshna
    Burdick, Daniel
    Griffith, Alida F.
    Madan, Arina
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (10): : 625 - 634
  • [3] ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia
    Pahwa, Rajesh
    Hauser, Robert A.
    JAMA NEUROLOGY, 2017, 74 (12) : 1507 - 1508
  • [4] Randomized, Placebo-Controlled Trial of ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 3)
    Oertel, Wolfgang
    Eggert, Karla
    Pahwa, Rajesh
    Tanner, Caroline M.
    Hauser, Robert A.
    Trenkwalder, Claudia
    Ehret, Reinhard
    Azulay, Jean Philippe
    Isaacson, Stuart
    Felt, Larissa
    Stempien, Mary Jean
    MOVEMENT DISORDERS, 2017, 32 (12) : 1701 - 1709
  • [5] ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia Reply
    Shukla, Aparna Wagle
    JAMA NEUROLOGY, 2017, 74 (12) : 1508 - 1508
  • [6] Update to interim results of a long-term open-label safety study of ADS-5102 (amantadine HCl) extended-release capsules for treatment of levodopa-induced dyskinesia (LID) (EASE LID 2 Study)
    Hauser, Robert
    Pahwa, Rajesh
    Tanner, Caroline
    Oertel, Wolfgang
    Johnson, Reed
    Felt, Larissa
    Stempien, Mary
    MOVEMENT DISORDERS, 2017, 32 : S42 - S43
  • [7] ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
    Hauser, Robert A.
    Pahwa, Rajesh
    Tanner, Caroline M.
    Oertel, Wolfgang
    Isaacson, Stuart H.
    Johnson, Reed
    Felt, Larissa
    Stempien, Mary Jean
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (03) : 511 - 522
  • [8] The Development of ADS-5102 (Amantadine ER Capsules) for the Treatment of Levodopa-induced Dyskinesia
    McClure, Natalie
    NEUROTHERAPEUTICS, 2015, 12 (03) : 679 - 680
  • [9] Pooled Analysis of Phase 3 Studies of ADS-5102 (Amantadine) Extended Release Capsules for Levodopa-Induced Dyskinesia: A Detailed Review of UDysRS Results
    Pahwa, Rajesh
    Hauser, Robert
    Tanner, Caroline
    Isaacson, Stuart
    Johnson, Reed
    Felt, Larissa
    Patni, Rajiv
    ANNALS OF NEUROLOGY, 2017, 82 : S86 - S86
  • [10] Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results
    Pahwa, Rajesh
    Tanner, Caroline
    Hauser, Robert
    Isaacson, Stuart
    Johnson, Reed
    Felt, Larissa
    Stempien, Mary Jean
    NEUROLOGY, 2017, 88
12345